{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:30:54Z","timestamp":1761863454790,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2015,9,3]],"date-time":"2015-09-03T00:00:00Z","timestamp":1441238400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100006484","name":"Vifor Pharma (CH)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s40273-015-0320-9","type":"journal-article","created":{"date-parts":[[2015,9,2]],"date-time":"2015-09-02T05:50:32Z","timestamp":1441173032000},"page":"1311-1324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland"],"prefix":"10.1007","volume":"33","author":[{"given":"Florian S.","family":"Gutzwiller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alena M.","family":"Pfeil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zanfina","family":"Ademi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia R.","family":"Blank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter G.","family":"Braunhofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas D.","family":"Szucs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Schwenkglenks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,9,3]]},"reference":[{"issue":"14","key":"320_CR1","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1056\/NEJMra0912522","volume":"362","author":"M Tonelli","year":"2010","unstructured":"Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med. 2010;362(14):1312\u201324.","journal-title":"N Engl J Med"},{"issue":"4","key":"320_CR2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","volume":"31","author":"GA Block","year":"1998","unstructured":"Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium\u00a0\u00d7\u00a0phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31(4):607\u201317.","journal-title":"Am J Kidney Dis"},{"key":"320_CR3","volume-title":"The Renal Association\u2014haemodialysis guidelines","author":"R Mactier","year":"2009","unstructured":"Mactier R, Hoenich N, Breen C. The Renal Association\u2014haemodialysis guidelines. Petersfield: The Renal Association; 2009."},{"key":"320_CR4","unstructured":"European and US Renvela Sales Data. http:\/\/www.imshealth.com and http:\/\/www.drugs.com\/stats\/renvela . Accessed 15 Apr 2015."},{"issue":"4","key":"320_CR5","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/ndt\/14.4.863","volume":"14","author":"O Hergesell","year":"1999","unstructured":"Hergesell O, Ritz E. Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients. Nephrol Dial Transplant. 1999;14(4):863\u20137.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"320_CR6","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.2014.58","volume":"86","author":"J Floege","year":"2014","unstructured":"Floege J, Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014;86(3):638\u201347.","journal-title":"Kidney Int"},{"issue":"6","key":"320_CR7","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/ndt\/gfv006","volume":"30","author":"J Floege","year":"2015","unstructured":"Floege J, Covic AC, Ketteler M, Mann JFE, Rastogi A, Spinowitz B, et al. Long-term effects of iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant. 2015;30(6):1037\u201346.","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"320_CR8","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1001\/jama.2011.308","volume":"305","author":"SC Palmer","year":"2011","unstructured":"Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA. 2011;305(11):1119\u201327.","journal-title":"JAMA."},{"issue":"1 Suppl 1","key":"320_CR9","first-page":"S1","volume":"55","author":"AJ Collins","year":"2010","unstructured":"Collins AJ, Foley RN, Herzog C, Chavers BM, Gilbertson D, Ishani A, et al. Excerpts from the US Renal Data System 2009 Annual Data Report. Am J Kidney Dis. 2010;55(1 Suppl 1):S1\u2013420 (A6\u20137).","journal-title":"Am J Kidney Dis."},{"issue":"3","key":"320_CR10","first-page":"e012137","volume":"10","author":"Y Wang","year":"2015","unstructured":"Wang Y, Xie G, Huang Y, Zhang H, Yang B, Mao Z. Calcium acetate or calcium carbonate for hyperphosphataemia of hemodialysis patients: a meta-analysis. PLoS One. 2015;10(3):e012137.","journal-title":"PLoS One"},{"key":"320_CR11","volume-title":"Hyperphosphataemia in chronic kidney disease","author":"National Institute for Clinical Excellence","year":"2013","unstructured":"National Institute for Clinical Excellence. Hyperphosphataemia in chronic kidney disease. Manchester: National Institute for Clinical Excellence; 2013."},{"key":"320_CR12","unstructured":"Scottish Renal Registry report 2013. Edinburgh: NHS National Services Scotland; 2014."},{"issue":"6","key":"320_CR13","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0197-2456(03)00072-2","volume":"24","author":"KJ Carroll","year":"2003","unstructured":"Carroll KJ. On the use and utility of the Weibull model in the analysis of survival data. Control Clin Trials. 2003;24(6):682\u2013701.","journal-title":"Control Clin Trials"},{"key":"320_CR14","unstructured":"The Renal Association UK Renal Registry Report 2013. Bristol: National Health Service England; 2013."},{"issue":"4","key":"320_CR15","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1524-4733.2007.00308.x","volume":"11","author":"YS Liem","year":"2008","unstructured":"Liem YS, Bosch JL, Hunink MG. Preference-based quality of life of patients on renal replacement therapy: a systematic review and meta-analysis. Value Health. 2008;11(4):733\u201341.","journal-title":"Value Health."},{"key":"320_CR16","unstructured":"Joint Formulary Committee. British National Formulary 69. British National Formulary; 2015."},{"key":"320_CR17","unstructured":"Curtis L. Unit costs of health and social care 2012. Kent: Personal Social Services Research Unit, University of Kent; 2012. Report No.: 978-1-902671-82-6."},{"key":"320_CR18","unstructured":"NHS reference costs: financial year 2011 to 2012. Department of Health; 2012."},{"key":"320_CR19","unstructured":"National Health Service. Cost-effectiveness of transplantation. NHS Blood and Transplant. 2009. http:\/\/www.organdonation.nhs.uk\/newsroom\/fact_sheets\/cost_effectiveness_of_transplantation.asp . Accessed 2 Nov 2013."},{"issue":"6","key":"320_CR20","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/TP.0b013e318199cfc9","volume":"87","author":"V Hamidi","year":"2009","unstructured":"Hamidi V, Andersen MH, Oyen O, Mathisen L, Fosse E, Kristiansen IS. Cost effectiveness of open versus laparoscopic living-donor nephrectomy. Transplantation. 2009;87(6):831\u20138.","journal-title":"Transplantation"},{"issue":"3","key":"320_CR21","doi-asserted-by":"crossref","first-page":"iii73","DOI":"10.1093\/ndt\/gfs269","volume":"27","author":"M Kerr","year":"2012","unstructured":"Kerr M, Bray B, Medcalf J, O\u2019Donoghue DJ, Matthews B. Estimating the financial cost of chronic kidney disease to the NHS in England. Nephrol Dial Transplant. 2012;27(3):iii73\u201380.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"320_CR22","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2215\/CJN.00290109","volume":"4","author":"YW Chiu","year":"2009","unstructured":"Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009;4(6):1089\u201396.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"320_CR23","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/ndt\/gft280","volume":"29","author":"S Wang","year":"2014","unstructured":"Wang S, Alfieri T, Ramakrishnan K, Braunhofer P, Newsome BA. Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis. Nephrol Dial Transplant. 2014;29(11):2092\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"320_CR24","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1185\/030079907X242719","volume":"23","author":"SM Sprague","year":"2007","unstructured":"Sprague SM. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. Curr Med Res Opin. 2007;23(12):3167\u201375.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"320_CR25","doi-asserted-by":"crossref","first-page":"104","DOI":"10.5414\/CNP62104","volume":"62","author":"J Braun","year":"2004","unstructured":"Braun J, Asmus HG, Holzer H, Brunkhorst R, Krause R, Schulz W, et al. Long-term comparison of a calcium-free phosphate binder and calcium carbonate: phosphorus metabolism and cardiovascular calcification. Clin Nephrol. 2004;62(2):104\u201315.","journal-title":"Clin Nephrol"},{"issue":"6","key":"320_CR26","first-page":"785","volume":"25","author":"FA Shaheen","year":"2004","unstructured":"Shaheen FA, Akeel NM, Badawi LS, Souqiyyeh MZ. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients. Saudi Med J. 2004;25(6):785\u201391.","journal-title":"Saudi Med J"},{"issue":"8","key":"320_CR27","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.jval.2011.05.043","volume":"14","author":"H Park","year":"2011","unstructured":"Park H, Rascati KL, Keith MS, Hodgkins P, Smyth M, Goldsmith D, et al. Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective. Value Health. 2011;14(8):1002\u20139.","journal-title":"Value Health"},{"issue":"1","key":"320_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3111\/13696998.2012.718019","volume":"16","author":"L Bernard","year":"2013","unstructured":"Bernard L, Mendelssohn D, Dunn E, Hutchison C, Grima DT. A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom. J Med Econ. 2013;16(1):1\u20139.","journal-title":"J Med Econ"},{"issue":"1","key":"320_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2191-1991-1-1","volume":"1","author":"T Plagemann","year":"2011","unstructured":"Plagemann T, Prenzler A, Mittendorf T. Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia. Health Econ Rev. 2011;1(1):1.","journal-title":"Health Econ Rev"},{"issue":"12","key":"320_CR30","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.2215\/CJN.04100609","volume":"4","author":"Q Fan","year":"2009","unstructured":"St Peter WL, Fan Q, Weinhandl E, Liu J. Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare and Medicaid services data. Clin J Am Soc Nephrol. 2009;4(12):1954\u201361.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"320_CR31","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.clinthera.2012.06.006","volume":"34","author":"S Vegter","year":"2012","unstructured":"Vegter S, Tolley K, Keith MS, Lok CE, Soroka SD, Morton AR. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective. Clin Ther. 2012;34(7):1531\u201343.","journal-title":"Clin Ther"},{"issue":"1","key":"320_CR32","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1524-4733.2006.00142.x","volume":"10","author":"A Brennan","year":"2007","unstructured":"Brennan A, Akehurst R, Davis S, Sakai H, Abbott V. The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease. Value Health. 2007;10(1):32\u201341.","journal-title":"Value Health"},{"key":"320_CR33","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1007\/s12325-014-0170-4","volume":"31","author":"K Ramakrishnan","year":"2014","unstructured":"Ramakrishnan K, Braunhofer P, Newsome B, Lubeck D, Wang S, Deuson J, et al. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a medicare cost-offset model. Adv Ther. 2014;31:1272\u201386.","journal-title":"Adv Ther"},{"issue":"5","key":"320_CR34","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.2215\/CJN.04741107","volume":"3","author":"R Mehrotra","year":"2008","unstructured":"Mehrotra R, Martin KJ, Fishbane S, Sprague SM, Zeig S, Anger M, et al. Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. Clin J Am Soc Nephrol. 2008;3(5):1437\u201345.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"320_CR35","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1093\/ndt\/gfs400","volume":"27","author":"R Kramann","year":"2012","unstructured":"Kramann R, Floege J, Ketteler M, Marx N, Brandenburg VM. Medical options to fight mortality in end-stage renal disease: a review of the literature. Nephrol Dial Transplant. 2012;27(12):4298\u2013307.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"320_CR36","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/1753944713513061","volume":"7","author":"A Rastogi","year":"2013","unstructured":"Rastogi A. Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease. Ther Adv Cardiovasc Dis. 2013;7(6):322\u201342.","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"16","key":"320_CR37","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1517\/14656566.2010.526107","volume":"11","author":"P Biggar","year":"2010","unstructured":"Biggar P, Kettler M. Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III\u2013V). Expert Opin Pharmacother. 2010;11(16):2739\u201350.","journal-title":"Expert Opin Pharmacother"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-015-0320-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-015-0320-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-015-0320-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T22:55:05Z","timestamp":1567119305000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-015-0320-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,3]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["320"],"URL":"https:\/\/doi.org\/10.1007\/s40273-015-0320-9","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"type":"print","value":"1170-7690"},{"type":"electronic","value":"1179-2027"}],"subject":[],"published":{"date-parts":[[2015,9,3]]}}}